JAKAVI under the microscope: new study tracks GVHD treatment in real life

NCT ID NCT07594587

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is tracking the safety and effectiveness of the drug JAKAVI (ruxolitinib) in 395 patients with graft-versus-host disease (GVHD), a complication of bone marrow transplants. Researchers are monitoring infections and other side effects in patients receiving the drug in routine clinical care. The goal is to see how well JAKAVI works outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib (JAKAVI)
What this could lead to: If successful, this study could confirm that ruxolitinib is a safe and effective option for managing graft-versus-host disease in everyday medical practice.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. Infections are a known risk with ruxolitinib, and the study focuses on safety monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease chronic graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT-VERSUS-HOST DISEASE

Contacts and locations

Locations

Novartis
RECRUITING

Tokyo, 105-6333, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.